AUS
NZ
UK
CA
USA
IND
Highlights
- FDA approval boosts Mesoblast (MSB) with new therapy Ryoncil.
- Ryoncil marks the first approved therapy for SR-aGvHD in the US.
- Mesoblast secures strong market positioning for innovative cell therapy.
Biotech company Mesoblast (ASX:MSB) witnessed a significant surge in its share price following the US Food and Drug Administration (FDA) approval of Ryoncil, a groundbreaking mesenchymal stromal cell therapy. This approval is a pivotal milestone for the company, positioning Ryoncil as the first FDA-approved therapy for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two months and older.
SR-aGvHD is a critical condition often observed in patients undergoing bone marrow transplants, with high mortality rates and limited treatment options. In clinical trials, Ryoncil demonstrated a remarkable response rate, with 70% of children achieving an overall response by the 28th day of treatment. This promising measure offers hope for improved survival outcomes in affected patients.
The approval also brings focus to the broader impact of Ryoncil. Approximately 10,000 patients undergo allogeneic bone marrow transplants in the US annually, with around 50% developing aGvHD. For children and adults who fail to respond to steroid treatments, Ryoncil now offers a much-needed alternative.
Mesoblast (MSB) is preparing to commercialize Ryoncil in the US, ensuring availability at transplant centers and treating hospitals. To support this launch, the company plans to use proceeds from a recent fundraising initiative involving its largest shareholder. In September, Mesoblast announced it would raise up to USD 50 million to bolster the commercial rollout of Ryoncil.
The company's chief executive, Silviu Itescu, emphasized their commitment to addressing unmet medical needs, particularly for vulnerable patients. He highlighted Ryoncil as a significant advancement for the GVHD community and reiterated the company's ongoing efforts to expand indications for the therapy. Additionally, Mesoblast is pursuing regulatory approvals for other late-stage products, including Revascor, aimed at cardiovascular diseases, and rexlemestrocel-L, targeting inflammatory pain indications.
The FDA's approval of Ryoncil marks a transformative moment for Mesoblast (MSB), solidifying its presence in the biotech sector. With a robust portfolio of innovative cell therapies in development, the company is poised to make further strides in addressing critical health challenges worldwide.
